Cite

HARVARD Citation

    Solomon, B. et al. (n.d.). 1380PDEfficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations. Annals of oncology. p. . [Online]. 
  
Back to record